Tiziana amends report for securities registrations

Tiziana Life Sciences Ltd amended its earlier Form 6-K solely to incorporate the information in that report, including Exhibit 99.1, by reference into its Form F-3 and Form S-8 registration statements.

Available on EDGAR 11/02/2026 - 09:15 AM EST Accepted by SEC EDGAR 11/02/2026 - 09:14 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Tiziana Life Sciences Ltd amended its earlier Form 6-K solely to incorporate the information in that report, including Exhibit 99.1, by reference into its Form F-3 and Form S-8 registration statements.

Key Terms

incorporated by reference, Form F-3, Form S-8

3 terms

incorporated by reference regulatory

"incorporated by reference into the Company’s Registration Statement"

Form F-3 regulatory

"Registration Statement on Form F-3"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

Form S-8 regulatory

"Form S-8"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K/A

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

November 2026

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K/A

This Amendment No. 1 on Form 6-K/A (this “Amendment”) amends the Report on Form 6-K furnished by Tiziana Life Sciences LTD to the Securities and Exchange Commission (the “SEC”) on October 16, 2026 (the “Original Form 6-K”) solely to provide that the information contained in the Original Form 6-K, including Exhibit 99.1 thereto, is incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-286064) and Form S-8 (Reg. No. 333-293620).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: November 2, 2026	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2